Navigation Links
Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
Date:4/9/2008

tainties. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including: statements regarding the Company's growth, future operating results, discovery, development of products and strategic alliances; statements regarding the potential number of patients eligible to benefit from VELCADE; statements regarding the merger agreement between Millennium and Takeda; any statements of expectation or belief; and any statements of assumptions underlying any of the foregoing. Employees, investors and security holders are cautioned not to place undue reliance on these forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause Millennium's results to differ from expectations include: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; Millennium's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing Millennium's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; uncertainties as to the timing of the transactions contemplated by the merger agreement; uncertainties as to how many of the Millennium's stockholders will tender their stock in the Offer; the risk that competing offers will be made; the possibility that
'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Millennium Announces $200,000 Purchase Order From Greek Distributor
2. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
3. Millennium Over-Delivers on 2007 Goals and Financial Guidance
4. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
5. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
6. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
7. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
8. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
9. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
10. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
11. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... bio-mimicking analog of one of nature,s most efficient ... team led by Alejandro Briseno of the University ... in developing long-sought polymer architecture to boost power-conversion ... electronic devices. , Briseno, with colleagues and ... Stanford University and Dresden University of Technology, Germany, ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... Sept. 30, 2014 CORD:USE Cord Blood Bank ... that it has entered into an Equity and Exclusive ... has licensed a series of patented technologies for the isolation ... clinical applications.  Tianhe is performing Phase I/II clinical trials ... Spain using Tianhe,s Stem Cell Educator Therapy ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... from North Carolina State University shows that size plays ... hollow nanoparticles. The researchers focused on nickel nanoparticles, which ... applications in fields as diverse as energy production and ... potential for nanofabrication the creation of materials that ...
... push the boundaries of nanoscience, the Kavli Institute at Cornell ... new ideas, but a proving ground to aggressively push the ... named Paul McEuen, the Goldwin Smith Professor of Physics, as ... engineering physics, will serve as co-director. The institute ...
... Choi of the Department of Mechanical Engineering at Stevens ... the 2010 Young Investigator Program (YIP) award by the ... scientists and engineers who show exceptional promise for creative ... young outstanding scientists and engineers," said ONR,s Director of ...
Cached Biology Technology:Study shows that size affects structure of hollow nanoparticles 2Under new leadership, Kavli Institute at Cornell evolves from a think tank to a proving ground 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 3
(Date:9/30/2014)... England Journal of Medicine reports positive results of ... against the subset of lung cancer marked by rearrangement ... 50 patients with advanced non-small cell lung cancer testing ... 72 percent, with 3 complete responses and 33 partial ... for the disease to resume its growth after being ...
(Date:9/30/2014)... German . ... foods in the world. Because they grow underground, people use ... smell of truffles is not only of interest to gourmets. ... of the Goethe University Frankfurt have discovered that the smell ... are trapped inside truffle fruiting bodies. , White truffles from ...
(Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... in German . , Jena/Leipzig. For ... extended cultivation of energy crops. Scientists have now developed ... comparing the effectiveness of strategies for the reduction of ... leads to problems to biological diversity in agrarian regions. ...
... 2012  The Intellectual Property & Science division of ... information for businesses and professionals, today announced the ... the life sciences market, a new initiative aimed ... information through application-specific solutions developed with third-party partners. ...
... With more than 1.7 million people sustaining a traumatic ... to limit inflammation and subsequent damage is critical. Approximately ... leaving 85,000 with long-term disabilities and taking the lives ... live with disabilities caused by traumatic brain injuries, often ...
Cached Biology News:How the ecological risks of extended bioenergy production can be reduced 2How the ecological risks of extended bioenergy production can be reduced 3Thomson Reuters Launches Life Sciences Partner Ecosystem to Drive Collaborative R&D Drug Processes 2Estrogen hormone reveals protective ability after traumatic brain injury 2